Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
This study offers a more comprehensive insight into the monitoring, supervision, and management of adverse drug reactions associated with IMI/CIL. Clinicians should pay further attention to the implications of numerous AEs and their corresponding signal intensities, as well as unrecorded signals of severe AEs. This holds significant value in enhancing the clinical safety profile of IMI/CIL.
Authors
- Peng Jia (ORCID: https://orcid.org/0000-0002-3124-3924)
- Jiangliu Yin
- Yiqian Lian (ORCID: https://orcid.org/0000-0002-2163-0189)
- Quirino Lai (ORCID: https://orcid.org/0000-0003-1487-3235)
- Yuan Gao (ORCID: https://orcid.org/0000-0002-3129-211X)
- Shangyu Wang (ORCID: https://orcid.org/0000-0003-0666-7167)
- Yusen Zhou (ORCID: https://orcid.org/0000-0002-7301-4089)
Institutions
- Changsha Central Hospital (CN)
- Xijing Hospital (CN)
- University of South China (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fphar.2025.1524159
- Citations
- 6
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 7.84